Web Analytics
IONS (NASDAQ) Stock Analysis | IONIS PHARMACEUTICALS INC – Deepscope
MARKET

Select Market Data Region

IONS — IONIS PHARMACEUTICALS INC (Healthcare >> Biotechnology)

IONS FAQ

What is IONS's P/E ratio?

IONIS PHARMACEUTICALS INC (IONS) currently trades at a P/E ratio of 100.83.

What is IONS's ROE?

IONIS PHARMACEUTICALS INC reports a Return on Equity (ROE) of -66.46%.

What is IONS's dividend yield?

IONIS PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is IONS's Deepscope Quality Score?

Deepscope rates IONS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy IONS?

Deepscope's AI Timing Score for IONS is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does IONS belong to?

IONIS PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-05-26 | FS: 2026-03-31)

IONS

IONIS PHARMACEUTICALS INC
USD 76.07
0.29 (0.38%) Day Change
100.83
P/E
3.63
D/E
-66.5%
ROE
-9.5%
ROA
0.00%
Div Yield
9.56
PEG
USD 76.07
Price
0.29 (0.38%)
Day Change
NEWS SCORE: 99

IONS, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

46

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors 42%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 99
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 76.07
  PBV / Sector
25.35 / 4.53
  Earning Per Share -1.99
  PE / Sector
100.83 / 16.80
  PEG or PE/Growth / Sector
9.56 / 0.51
  Average 1M Daily Value
131.98 M
GREAT
  Average 1W Daily Value
131.68 M
GREAT
Timing Factors 71%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Financial Health 41%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Ability to Make Profit 52%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
-30.87 / 450.37
  NPM Average (%) / Sector
-45.61 / -1,506.30
  NPM Change Average (%) / Sector
-5.28 / 4,941.44
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-9.47 / 30.83
  ROA Average (%) / Sector
-11.66 / -347.12
  ROA Change Average (%) / Sector
-0.61 / 5,126.35
  ROE (%) / Sector
-66.46 / -3.04
  ROE Average (%) / Sector
-72.66 / 40.76
  ROE Change Average (%) / Sector
17.23 / 2,110.63
GOOD
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Return to Investors 4%
X
  Dividend (%) / Sector
N/A / 0.05
  Dividend Average (%) / Sector
N/A / 16.49
  Dividend Change Average (%) / Sector
N/A / 4.43
Registration Details
X
  Analyze Date 2026-06-03 09:10:54
  Symbol IONS
  Name IONIS PHARMACEUTICALS INC
  Sector Healthcare >> Biotechnology
  Market NASDAQ
  Listed Shares 165.26 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 12,457.49 / 8,614.17
News, Concensus, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 2855 Gazelle Court, Carlsbad, CA, United States, 92010

Phone: 760 931 9200

Website: https://www.ionis.com

Employees: 1,402

Sector: Healthcare >> Biotechnology

Description: Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

ME vs SECTOR Healthcare >> Biotechnology

IONS (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
IONS
IONS
USD 76.07 (0.38%)
+ Watch + Port Chart